Telesta Therapeutics Announces Issuan...
Home  »  Community News  »  Telesta Therapeutics...
Telesta Therapeutics Announces Issuance of Key U.S. MCNA Composition of Matter Patent
Pharma News

MONTREAL, June 3, 2015 /PRNewswire/ – Telesta Therapeutics Inc. (TSX:TST; PNK:BNHLF) announced today, that the United States Patent and Trademark Office has issued U.S. Patent No. 9,044,422, which provides intellectual property (IP) protection for Telesta’s Mycobacterium phlei cell wall-nucleic acid complex (MCNA) composition of matter.  MCNA is Telesta’s late stage biologic developed for the treatment of high-grade non-muscle invasive bladder cancer in patients who have failed first-line BCG treatment.  As previously reported, Telesta is targeting the filing of a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for this therapeutic by the end of June.

Commenting on the issuance of this patent, Dr. Michael Berendt, CEO and Chief Scientist noted: “We are extremely pleased with the issuance of this U.S. composition of matter patent which provides strong IP coverage in the largest and most important commercial market for MCNA.  This patent is a key component of our IP portfolio and will provide intellectual property protection for at least 16 years, which is a major advantage as we look forward to commercial approval in 2016.”

This U.S. patent issuance adds to Telesta’s growing portfolio of issued MCNA patents, with recent awards in Australia and South Africa.  Telesta is continuing to actively pursue MCNA patent protection across all of the key global pharmaceutical markets.

As part of its ongoing efforts to increase its global visibility and explore multiple strategic opportunities, Telesta will be participating in the 2015 BIO International Convention in Philadelphia from June 15-18, 2015.

About Telesta Therapeutics Inc.

Telesta Therapeutics Inc. is a late stage therapeutics company with near term commercial potential focused on the manufacturing, marketing and licensing/acquisition of proprietary and innovative therapies for the global health market with a focus on MCNA, its late stage uro-oncology therapeutic. The Company’s primary goal is to develop and commercialize products that advance human health and increase shareholder value. For more information, please visit

Except for historical information, this news release may contain “forward-looking statements” and “forward-looking information” within the meaning of applicable securities laws that reflect the Company’s current expectation regarding future events. Forward-looking statements and information are necessarily based upon a number of estimates and assumptions that, while, considered reasonable by management, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Readers are cautioned that any such forward-looking statements and information are not guarantees and there can be no assurance that such statements and information will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements and information. These forward-looking statements and information involve risk and uncertainties, which may cause, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company’s ongoing quarterly and annual reporting. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements and information whether as a result of new information, future events or otherwise. All written and oral forward-looking statements and information attributable to us or persons acting on our behalf are expressly qualified in their entirety by the foregoing cautionary statements.

SOURCE Telesta Therapeutics Inc.

Leave a reply

You must be logged in to post a comment.